Doxorubicin
- Generic Name
- Doxorubicin
- Brand Names
- Adriamycin, Doxil, Myocet, Caelyx pegylated liposomal, Zolsketil pegylated liposomal, Myocet liposomal (previously Myocet), Celdoxome pegylated liposomal
- Drug Type
- Small Molecule
- Chemical Formula
- C27H29NO11
- CAS Number
- 23214-92-8
- Unique Ingredient Identifier
- 80168379AG
- Background
Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970. Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin. Although its deta...
- Indication
Doxorubicin is indicated for the treatment of neoplastic conditions like acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin and non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilmsโ tumor, metastatic neuroblastoma, metastatic soft tissue and bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinom...
- Associated Conditions
- AIDS-related Kaposi's Sarcoma, Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Advanced Endometrial Cancer, Advanced Ovarian Cancer, Breast Cancer, Hodgkin's Lymphoma, Metastatic Bone Sarcomas, Metastatic Breast Cancer, Metastatic Soft Tissue Sarcoma, Metastatic Thyroid Cancer, Metastatic Urothelial Cancer, Multiple Myeloma (MM), Mycosis Fungoides (MF), Non-Hodgkin's Lymphoma (NHL), Sezary Syndrome, Waldenstrรถm's Macroglobulinemia (WM), Advanced Thymoma, Advanced uterine sarcoma, Metastatic Bronchogenic Carcinoma, Metastatic Gastric carcinoma, Metastatic Neuroblastoma, Metastatic Ovarian carcinoma, Metastatic Wilms' tumor
- Associated Therapies
- -
Comparison of Different Combination Chemotherapy Regimens in Treating Children With Acute Lymphoblastic Leukemia
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-02-23
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 3054
- Registration Number
- NCT00005945
- Locations
- ๐บ๐ธ
Medical City Dallas Hospital, Dallas, Texas, United States
๐บ๐ธIreland Cancer Center at University Hospitals of Cleveland and Case Western Reserve University, Cleveland, Ohio, United States
๐บ๐ธMD Anderson Cancer Center at University of Texas, Houston, Texas, United States
Combination Chemotherapy Plus Biological Therapy in Treating Patients With Stage II or Stage III Breast Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2015-05-05
- Lead Sponsor
- Roger Williams Medical Center
- Registration Number
- NCT00022230
- Locations
- ๐บ๐ธ
Roger Williams Medical Center, Providence, Rhode Island, United States
Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2021-04-29
- Lead Sponsor
- NSABP Foundation Inc
- Target Recruit Count
- 2130
- Registration Number
- NCT00004067
- Locations
- ๐บ๐ธ
Cancer Care Center at Northside Medical Center, Youngstown, Ohio, United States
๐บ๐ธCarole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center, Farmington, Connecticut, United States
๐บ๐ธCancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States
Combination Chemotherapy Followed By Antiviral Therapy and Interferon Alfa in Treating Patients With HTLV-1-Related Adult T-Cell Leukemia/Lymphoma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-02-03
- Lead Sponsor
- AIDS Malignancy Consortium
- Target Recruit Count
- 19
- Registration Number
- NCT00041327
- Locations
- ๐บ๐ธ
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
๐บ๐ธUniversity of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States
๐บ๐ธSiteman Cancer Center at Barnes-Jewish Hospital, Saint Louis, Missouri, United States
Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 105
- Registration Number
- NCT00039130
- Locations
- ๐บ๐ธ
University of Illinois Cancer Center, Chicago, Illinois, United States
๐บ๐ธUniversity of Chicago Cancer Research Center, Chicago, Illinois, United States
๐บ๐ธGreenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States
Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing's Sarcoma or Neuroectodermal Tumor
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2023-08-03
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 587
- Registration Number
- NCT00006734
- Locations
- ๐บ๐ธ
University of Chicago Cancer Research Center, Chicago, Illinois, United States
๐บ๐ธRush University Medical Center, Chicago, Illinois, United States
๐บ๐ธUniversity of Illinois Medical Center, Chicago, Illinois, United States
Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-07-19
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 78
- Registration Number
- NCT00032019
- Locations
- ๐บ๐ธ
Cedars-Sinai Comprehensive Cancer Center at Cedars-Sinai Medical Center, Los Angeles, California, United States
๐บ๐ธBroward General Medical Center, Fort Lauderdale, Florida, United States
๐บ๐ธMemorial Regional Hospital Comprehensive Cancer Center, Hollywood, Florida, United States
Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers
- First Posted Date
- 2003-01-08
- Last Posted Date
- 2021-09-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 62
- Registration Number
- NCT00051311
- Locations
- ๐บ๐ธ
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
A Randomized Study of the Effect of Adjuvant Chemotherapy With Doxorubicin and Ifosfamide With Mesna in the Treatment of High-Grade Adult Extremity Soft Tissue Sarcoma
- Conditions
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 150
- Registration Number
- NCT00001300
- Locations
- ๐บ๐ธ
National Cancer Institute (NCI), Bethesda, Maryland, United States
A Pilot Trial of AC (Adriamycin, Cyclophosphamide) Chemotherapy With G-CSF (Granulocyte Colony-Stimulating Factor) Followed by Infusional Taxol (Paclitaxel) as Adjuvant Treatment for High Risk Stage II and Stage III Breast Cancer Patients
- Conditions
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 35
- Registration Number
- NCT00001384
- Locations
- ๐บ๐ธ
National Cancer Institute (NCI), Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.